Drug intelligence / Profile preview

GK567

Development stage: Unknown
Lead developer: Galderma
Modality: Small Molecules
Administration: Topical

Overview

Metronidazole 0.75% gel (GK567) is a topical formulation developed for the deodorization of malodorous fungating tumors. It works by inhibiting nucleic acid synthesis in anaerobic bacteria through the formation of nitroso radicals that disrupt microbial DNA. This mechanism is particularly effective in the low-oxygen environment of chronic wounds where anaerobic bacteria thrive and produce malodorous compounds.

Targets

Neuraminidase

Beyond the preview

Go deeper on GK567.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GK567.

Explore the full profile